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The phosphatidylinositol 3-kinase signaling pathway plays a central role in regulating the host inﬂammatory response. The net ef-
fectcaneitherbepro-oranti-inﬂammatorydependingonthesystemandcellularcontextstudied.Thispaperfocusesonphospha-
tidylinositol 3-kinase signaling in innate and adaptive immune cells of the intestinal mucosa. The role of phosphatidylinositol 3-
kinase signaling in mouse models of inﬂammatory bowel disease is also discussed. With the development of new isoform speciﬁc
inhibitors, we are beginning to understand the speciﬁc role of this complex pathway, in particular the role of the γ isoform in
intestinal inﬂammation. Continued research on this complex pathway will enhance our understanding of its role and provide
rationaleforthedesignofnewapproachestointerventioninchronicinﬂammatoryconditionssuchasinﬂammatoryboweldisease.
1. Phosphatidylinositol 3-Kinase Family
The phosphatidylinositol 3-kinases (PI3-K) are a family of
lipid kinases involved in a broad range of cellular responses
from cell cycle regulation, apoptosis, growth, and cell surviv-
al, making this a highly complex signaling network involved
in cellular homeostasis [1]. Dysregulation of this complex
pathway can lead to diseases such as cancer, inﬂammation,
and autoimmunity, all associated with inﬂammatory bowel
disease.
Phosphatidylinositol 3-kinases (PI3-K) phosphorylate
theD-3,OHpositionoftheinositolheadgroupsofphospho-
inositide lipids, phosphatidylinositol (PtdIns), phosphatidy-
linositol (4)-phosphate (PtdIns(4) P), and phosphatidyli-
nositol (4,5)-biphosphate (PtdIns(4,5) P2) [2]. This results
in the formation of PtdIns PIP, PtdIns(3,4) PIP2, and
PtdIns(3,4,5)PIP3,respectively.Theselipidsbindtotheplee-
ckstrin homology domains (PH) of proteins, thereby con-
trollingtheactivityandsubcellularlocalizationofavarietyof
signal transduction molecules. PI3-kinases can be divided
into3mainclassesonthebasisoftheirinvitrolipidsubstrate
speciﬁcity.
1.1. Class 1. The Class 1 PI3-Ks are a major focus of study as
it is these isoforms that are coupled to extracellular stimuli
[3]. The class 1A enzymes encode 5 regulatory subunits en-
coded by 3 separate genes, PIK3r1 encoding p85α and alter-
native transcripts, p50 and p55, PIK3r2, encoding p85β and
PIK3r3 encoding p55γ. These regulatory subunits each pair
with one of the class 1 catalytic subunits, p110α, p110β and
p110δ (Figure 1(a)).
The regulatory subunits function to recruit the complex
to the plasma membrane following receptor ligation. The in-
teraction between p85 and the receptor complex is mediated
by a high-aﬃnity interaction between the p85 Src homology
2 (SH2) domain and the speciﬁc tyrosine-phosphorylated
sequences within the cytoplasmic tail of the receptor. The
process recruits the p110 catalytic domain to the plasma
membrane where it phosphorylates its main substrate
PtdIns(4,5) P2 to generate PtdIns(3,4,5) P3. It has recently
been demonstrated that p85 itself is regulated by phosphory-
lation, and this determines its ability to associate with p110
[4]. Recruitment to the plasma membrane via association
of p85 with signaling complexes containing Shc, Grb2, and2 Journal of Signal Transduction
Class 1A PI3-K
p85 binding C2 PKC homology
C2 PKC homology
PIK domain
PIK domain
Class 1B PI3-K
p101 binding
p110γ
p110α/β/δ
G protein binding G protein binding
Catalytic domain
Catalytic domain
Ras binding
Ras binding
(a)
p110α/β/δ
p85
TIR
TIR
DD
pTyr
PTEN
TIR
DD
pTyr479
LBP
LPS
CD14
p85
p110α/β/δ
ras
p110γ
Class 1A Class 1A
Class 1B
p87
δ
γ
γ
TIR
TIR
DD
O
O
O
O
O
O
N
N
N
N
N
N N
N
N
N
H2N
F
F S
S
H H
O
CD11b
PIP2
TLR4
PIP3
IL-1R1
IL-1R
IL-1RAcP
PI5-K
MAL
MyD88
−
IC-87114
AS605240 AS604850
(b)
Figure 1: (a) domain structure of the catalytic subunits of the class 1 PI3-Kinases. Three genes PIK2CA, PIK3CB, and PIK3CD code for the
class 1A, p110α, β,a n dδ isoforms of PI3-K. They have an N-terminal p85 binding domain, a C-terminal catalytic domain, a ras binding
domain, a C2 (PKC homology domain), and a phosphatidylinositol kinase homology (PIK) domain. Class 1B is a heterodimer composed
of either a p101 or PIKAP (PI3-Kγ adapter protein of 87kDa) regulatory subunit and a catalytic p110γ subunit. GPCRs activate PI3-Kγ
throughinteractions withGβγ [9].Thecatalytic p110γ subunithas signiﬁcant sequence homology to class 1Acatalytic subunits; however, its
regulatory subunits, p101 and p87, are diﬀerent from p85. (b) class 1A and class 1B phosphatidylinositol 3-kinases are activated downstream
of toll/IL-1 receptors in myeloid cells, and selective isoform-speciﬁc inhibitors have been developed. Binding of LPS to CD14 likely induces
PI5-kinase to generate PIP2 downstream of integrin β2 (CD11) signaling [10]. LPS/CD14 interaction regulates steady state levels of PIP2 at
theplasmamembraneandthelocalizationoftheMALadaptorprotein.MALfacilitatestheTIR-mediatedrecruitmentoftheMyD88adaptor.
Tyrosinephosphorylationbyasrc-relatedkinaseontheTIRdomainofMAL/MyD88orotherTLR4adaptorservestorecruitSH2containing
protein p85, the PI3-K regulatory sub-unit. The catalytic subunits of PI3-K, p110, α, β and δ and γ isoforms mediate the phosphorylation
of PIP2 to PIP3. Downstream of the IL-1 receptor, a ras-dependent pathway to the activation of class 1B, PI3-Kinase γ isoform, has recently
been reported, associated with myeloid cell traﬃcking tumor growth and progression [8]. IC-87114 is the ﬁrst selective PI3-Kδ inhibitor.
This selectivity was unexpected given that the residues that line the ATP binding pocket of class 1 PI3-Ks are highly conserved. AS-604850
and AS-605240 are selective, ATP-competitive inhibitors of the PI3-Kγ isoform shown to inhibit intestinal inﬂammation in murine colitis
models.
Gab2 in response to cytokines such as interleukin-1 (IL-1)
has also been reported [5]. The catalytic subunit, p110, also
binds to activated ras which might also stabilize association
with the plasma membrane after recruitment to the receptor
c o m p l e xb yp 8 5 .C l a s s1 Ai s o f o r m sa r ea c t i v a t e dd o w n -
stream of T-cell receptors (TCRs) B-cell receptors (BCR)
and costimulatory receptors as well as cytokine receptors
that are phosphorylated by tyrosine kinases after receptor
engagement with ligand (Figure 1(a)) .C l a s s1 AP I 3 - K sh a v e
been proposed to act as negative regulators downstream of
toll-like receptor (TLR)-induced signaling thereby aﬀecting
IL-12 production by dendritic cells (DCs) [6, 7]. Thus,Journal of Signal Transduction 3
inhibition of PI3-Ks could upset the balance of Th1/Th2
responses. The class 1B isoform p110γ associates with one
of 2 regulatory subunits, p84/87 or p101 [5]. Until recently
it was thought that this class was downstream speciﬁcally
of G-protein-coupled receptor βγ subunits. However, it has
now been demonstrated that p110γ/p87 is also downstream
of toll-like receptors/IL-1 receptors in myeloid cells making
it a convergent point controlling tumor inﬂammation and
progression [8]( Figure 1(b)).
1.2. Class 2. These PI3-Ks, encompassing PI3-kinase-C2α,
C2β and C3γ are characterized by a C2 domain that mediate
calcium/lipid binding in protein kinase C isoforms. Class 2
PI3-Ks use (PtdIns(4) P) as their preferred substrate. Class 2
PI3-Kshavenotbeenisolatedinassociationwitharegulatory
subunit. This class binds to clathrin and their localization
t oc o a t e dp i t ss u g g e s t sar o l ei nm e m b r a n et r a ﬃcking and
receptor internalization [11].
1.3. Class 3. These PI3-Ks utilize only PtdIns as substrate
thus creating PtdIns(3) P. In mammalian cells, this kinase is
involved in the movement of proteins through the lysosome
[11]. The mechanism of activation of classes 2 and 3 PI3-Ks
in vivo is not fully understood as is their role in the immune
system.
2. Tissue Distribution,Feedback Regulation,
andPharmacological Inhibition
While PI3-Kα and β have a broad tissue distribution, PI3-
Kδ and γ are predominantly expressed in leukocytes. PI3-
Kδ is also expressed in neurons and in some cancers such
as breast and melanoma, while PI3-Kγ is also expressed
in endothelium and heart. There has been much interest
in the PI3-kδ and γ isoforms as they represent promising
targets for selective inhibition of PI3-K in inﬂammatory and
autoimmune conditions [12]. Although there is evidence
suggesting that PI3-Kδ and γ act in partnership, there is
also evidence that they play complimentary roles in the
immune system. Murine knockouts of the p110α and β
genes results in embryonic lethality with reports suggesting
that p110α plays a role in cell survival and p110β isoform
being important in cell proliferation. A mouse harboring
mutation in the p110δ isoform (D910A/D910A), although
viable and fertile, demonstrates B- and T-cell defects includ-
ing improper maturation, defective antigen receptor signal-
ing, and impaired humoral immune responses with a shift
towards Th2 responses. These mice develop chronic segmen-
tal colonic inﬂammation [12].
The PI3-Kδ isoform is crucial to the function of
CD4+CD25+FoxP3+ Treg cells which produce the anti-
inﬂammatory cytokine, IL-10. Using PI3-Kinase D910A−/−
mice, it was shown that PI3-Kδ plays a key role in Treg-
mediated suppression of CD4+CD25−T-cell proliferation
and inﬂammation. Mice expressing kinase inactive PI3-
Kδ develop a mild inﬂammatory bowel disease phenotype
which might be indicative of such a suppressive mechanism
[13]. The serious defects in immune development in double
knockoutPI3-Kγδ−/− micepreventadetailedunderstanding
oftheselectiverolesofthesesubunits.Knockoutofthep110γ
isoform in mice suggests that this isoform is critical for full
B- and T-cell antigen receptor signaling [14].
Negative feedback regulation of PI3-K signaling by the 3 
phosphatase PTEN (phosphatase and tensin homolog) and
the 5  phosphatase SHIP1 (SH2-domain containing inositol-
5-phosphatase 1) and SHIP2 is essential to control constitu-
tive activation and associated disease such as cancer. PTEN is
atumorsuppressormutatedordeletedinavarietyoftumors.
Cells lacking PTEN have elevated levels of PtdIns(3,4) P2
and PtdIns(3,4,5) P3 with constitutive activation of PI3-K.
SHIPhasanimportantroleinlymphocyteswithlossofSHIP
culminating in the development of autoimmunity. PTEN
and SHP2 are ubiquitously expressed while SHP2 is mainly
restricted to leukocytes [2].
As PI3-K has a function in normal immune homeostasis,
completeblockadeofPI3-Kactivitymaycompromiseimmu-
nityandincreasesusceptibilitytoinfectionsparticularlydur-
ing chronic inﬂammation. The ﬁrst generation PI3-K inhib-
itors, wortmannin, and LY294002 are unsuitable for thera-
peutic use because of the lack of stability and selectivity or
because of toxicity issues. As there is a high degree of amino
acid sequence homology between the ATP-amino acid bind-
ing pockets of the four class 1 PI3-Ks, the search for sel-
ective small molecule isoform speciﬁc PI3-K inhibitors
was challenging. The discovery of the quinazolinone
purine series of inhibitors by ICOS Corp with IC-87114,
demonstrating selective PI3-Kδ inhibition with negligi-
ble potency against PI3-Kα and β isoforms was an
important advance. Selective inhibition of PI3-Kγ has
also been accomplished by Merck Serono S.A. with AS-
605240 and AS-604850 [12]( Figure 1(b)). Dual speci-
ﬁcity, PI3-Kγ and δ, has been accomplished with TG-
100-115 from TargeGen. Pharmacological inhibition of
PI3-Kγ which is involved in immune eﬀector cell re-
cruitment may reduce immune surveillance. Therefore, cau-
tion should be taken when using selective PI3-Kγ inhibitors
as they could also potentially interfere with its nonimmune
function, for instance its’ involvement in cardiac contractil-
ity.RecentevidencethatPI3-Kβ andγ cancoupletothesame
GPCRs in a redundant manner may further limit the use-
fulness of these inhibitors in the immune system.
3.PI3-Kinase,Recruitment byIL-1,and
TLRFamilyReceptors
Innate immune responses are triggered through toll-like re-
ceptors (TLRs) that recognize a variety of microbial antigens
called pattern-associated molecular patterns (PAMPs). The
extracellular region contains leucine-rich repeat (LRRs) do-
mains specialized to recognize a speciﬁc microbial ligand.
TLRs and IL-1 receptors have in common a TIR domain
(toll/IL-1 receptor). The toll/Interleukin-1 receptor (TIR)
domain is the conserved intracellular domain of the two fa-
milies of receptors and is also shared by the downstream
adapter molecule MyD88. Upon receptor activation, it is be-
lieved that a TIR domain signaling complex is formed4 Journal of Signal Transduction
between the receptor and the adapter and is responsible
for mediating the downstream signaling generated by the
engagement between TLRs and the PAMPs (Figure 1(b))
[15]. In humans, 10 TLRs have been identiﬁed. We will focus
here on TLR4 and TLR5 which are the receptors for bacte-
rial lipopolysaccharide, LPS and the lipoproteins, ﬂagellin,
respectively. These TLRs reside on the plasma membrane
[16, 17] .C l a s s1 Aa n dc l a s s3P I 3 - K sh a v eb e e ns h o wnt op l a y
a role in TLR signaling [18]. Once activated PI3-K regulates
TLR signaling in both positive and negative ways. PI3-K
is believed to be a gate-keeper to control excessive innate
immune responses and is an early event in TLR signaling.
3.1. The Adaptor Proteins MyD88 and Mal Are Involved in
PI3-Kinase Recruitment by TLRs. TLR signaling pathways
have been studied extensively in the context of antigen
presentingcell(APC)function.AllTLRsexceptTLR3(ligand
for dsRNA) mediate signals through a pathway via the
TIR domain containing adaptor MyD88. MyD88 mediates
TLR signaling through 2 critical domains, the TIR domain
recruits MyD88 to the TLR after engagement and the MyD88
death domain (DD) couples TLR:MyD88 association to the
activation of downstream targets associated with inﬂamma-
tion. The cytosolic domains ofTLRs2,3, and5 allbeara con-
served YXXM, PI3-K consensus binding site. A recent study
demonstrated however that there was no such domain pre-
sent on the TLR4/LPS receptor, leaving open the question
whether the SH2-mediated association of p85 to TIR family
members is the only way of activating PI3-Kinase [19]. As
MyD88 is one of 4 adaptors that binds to TLR4 and it has
been reported that PI3-K mediated activation of NFκBd e -
pends on the MyD88 TIR domain and on the IRAK1 DD
death domain, it is likely that p85 binds to the MyD88 TIR
domain in response to TLR4 ligation [20] (Figures 1(b) and
2(a)).
Alignment of MyD88 TIR domains of several vertebrate
species reveals a highly phylogenetically conserved putative
SH2, YKXXM motif which was shown to promote PI3-K
recruitment in response to TLR9 stimulation [19]. Interest-
ingly, a dominant negative mutant of MAL (MyD88 adaptor-
like protein) had no eﬀe c to ne i t h e rI L - 1o rL P Sa c t i v a t i o no f
AKT [20]. More recently, it has been demonstrated that TIR-
containing Mal also directly interacts with the regulatory
subunit of PI3 kinase, p85α, and that Mal-p85α interaction
drives PI3K-dependent phosphorylation of Akt, PIP3 gener-
ation, and macrophage polarization [23].
3.2. PI3-Kinase Recruitment to the IL-1R Depends on MyD88,
IL-1RAcP, and IRAK. Interleukin-1 receptors are transmem-
brane glycoproteins which lack a catalytic domain. IL-1R
therefore recruits the serine/threonine kinase, interleukin-
receptor-associated kinase, IRAK. The C-terminal portion of
the IL-1R is essential for IL-1 signaling and therefore inter-
acts with accessory signaling components. IL-1 stimulation
induces aggregation of the IL-1R1 with the IL-1 receptor
accessory protein (IL-1RAcP) which increases the binding
aﬃnity of IL-1R [24]. The activated IL-1RAcP complex then
recruitsIRAKthroughbindingtoitscytoplasmictail.MyD88
is the adaptor protein that is involved in IL-1R and toll-
like receptor induction of NFκB and JNK. By directly bin-
ding IRAK-1 and IRAK-4, MyD88 serves as a bridging pro-
tein enabling IRAK-4-induced phosphorylation of IRAK-1
(Figures 1(b) and 2(c)).
AhighlyconservedconsensusbindingsiteforPI-3kinase
is present on the cytoplasmic domain of IL-1R (Tyr-E-X-
Met). The IL-1 receptor is tyrosine-phosphorylated in res-
ponse to IL-1 stimulation, and it was shown that, Tyr479 was
essential for PI3-kinase recruitment and activation [25]. In-
terestingly Tyr479 phosphorylation was also shown to be
upstream of NFκB activation. Both the N- and C-terminal
SH2 domains of p85 can bind the IL-1R. It was later de-
terminedthattheC-terminusoftheIL-1RAcPalsobindsp85
[26, 27]. The IL-1RAcP as well as MyD88 have similar con-
sensus binding sites for PI3 kinase. Although the IL-1LRAcP
does contain a C-terminal TIR domain, this does not appear
tobetyrosine-phosphorylatedinresponsetoIL-1[28].Itwas
later demonstrated that the terminal 26 aa of IL-1RacP was
essential for PI3-Kinase recruitment and activaton of NFκB
but had no eﬀect on activation of JNK/SAPK in response
to IL-1 [27]. Reddy et al. demonstrated that PI3-K was ac-
tivated by interleukin-1 and that IL-1 receptor activation in-
duced the association between the type 1 receptor and the
p85 regulatory subunit [29]. Further, wortmannin and a
dominant negative p85 subunit inhibited IL-1 activation of
both NFκB and AP-1.
The binding of IL-1 to the type 1 IL-1 receptor induces
cascades of intracellular events including activation of mito-
gen-activated protein kinases (MAPKs) involved in the ac-
tivation of AP-1 and IκB kinases (IKKs) involved in the ac-
tivation of NF-κB[ 24]. Activation of PI-3 kinase, by IL-1, is
suﬃcient for full activation of AP-1 but not NFκB( Figure 1)
[29].
Both IL-1R and TLRs activate the central MyD88-IRAK-
TRAF6signaling module.AlthoughPI3-Kinasecanbinddir-
ectlytotheIL-1R,ithasbeenshownusingODNoligonucleo-
tides as well as in IRAK1 deﬁcient cell lines that IL-1 activa-
tion of PI3-K also depends on IRAK1 and 2 suggesting its
involvement in the signaling modules [30]. Whereas IRAK1
appears to interact directly with the IL-1RAcP, IRAK-2 pre-
ferentially associates with the IL-1R [17]. To our knowledge
no protein-protein interaction between PI3-K and IRAK-1/2
has been reported and TRAF 6-mediated PI3-K function is
thought to be indirect via its association with the tyrosine
kinase Src [31]. In IRAK1 deﬁcient mouse embryo ﬁbrob-
lasts, neither IL-1 nor LPS induced AKT phosphorylation or
IL-6 gene induction, and reintroduction of IRAK-1 rendered
these cells fully responsive.
4. Role of PI3-Kinase Signaling
Downstreamof IL-1R,TLRs,andTCR
Costimulatory Molecules
The coordinated response of innate and adaptive immune
cells together with intestinal epithelial cells to luminal com-
mensal and pathogenic bacteria can result in dysregulation
of homeostasis resulting in inﬂammatory bowel disease.Journal of Signal Transduction 5
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Figure 2: (a). PI3-kinase/AKT/GSK3β pathway control of pro- and anti-inﬂammatory cytokine production in innate immune cells
determines the balance of Th1 and Th2 immune responses. Plextrin homology (PH) domain containing kinases, PDK, and AKT are
recruited to the plasma membrane and bind to PIP3. PDK phosphorylates AKT on Thr308 in the activation loop, and this is followed by
Ser473 phosphorylation. For MyD88-dependent signaling, TLR-mediated inhibition of GSK3, via AKT phosphorylation of its Ser 9 residue
leads to increases in DNA binding of cAmp response element binding protein 1 (CREB), which displaces the coactivator CBP from NFκB.
The increased CREB activity leads to production of the anti-inﬂammatory cytokine IL-10 (Th2 cytokine) and lowered IL-12 production.
Inhibition of PI3-K via dephosphorylation of PIP3 by the phosphatase PTEN enables GSK3 to remain active to inhibit transcription factors
such as cJun and CREB thereby decreasing IL-10, increasing NFκB-mediated IL-12 expression, and enhancing Th1 responses. (b) lamina
propria T (LPT) cells are hyporesponsive to TCR stimulation and use the alternative CD-2 pathway. PI3-kinase AKT/GSK3β pathway
downstream of CD-2 likely targets the AP-1 and NFAT sites on the IL-2 promoter. The activity of the PIP3 phosphatase, PTEN is likely
reducedinLPTcellsduetotheincreasedthioredoxin(TrX1)inthesecells.MultipleTCRstimulationofLPTcellshasbeenreportedtoinduce
FOXP3/IL-10producingimmunosuppressiveTregcells[21].(c)PI3-kinase-dependentpathwaystoIL-6genetranscriptioninresponsetoIL-
1 in Caco-2 intestinal epithelial cells. IL-1 binding to the IL-1R1 increases its aﬃnity for the co-receptor, the IL-1 receptor accessory protein
(IL-1RAcP). Formation of the signaling module containing the MyD88 adaptor protein together with phosphorylated IRAK (interleukin-1
receptor-associated kinase) and TRAF-6 (TNF receptor-associated factor) is essential for PI3-K recruitment and AKT activation. The TAK1
(TGFβ activated kinase) signaling module is likely a separate parallel pathway to NFκB activation. We identiﬁed 2 separate pathways to
the induction of IL-6 transcription in response to IL-1, the ﬁrst is a novel IKKα-dependent pathway involving phosphorylation of the T23
residue on IKKα, upstream of AP-1 (activator protein 1) activation, and the second is an AKT-dependent activation of NFκB, likely via
phosphorylation of the p65 subunit [22].6 Journal of Signal Transduction
This section discusses what is known about PI3-K signaling
downstream of these receptors in the relevant cell types.
4.1. Role of PI3-K Signaling in Innate Immune Cells
4.1.1. Dendritic Cells. Dendritic cells are important media-
tors of the innate immune response in the intestine. Den-
driticcellshavearichsupplyofpattern-recognitionreceptors
and are present within Peyers Patch and throughout the
lamina propria, producing extensions into the gut lumen to
sample luminal antigens. Human intestinal lamina propria
DCs express the MHC II marker HLA-DR. This lineage is
largely conventional CD11c+ myeloid DCs [32]. Most of the
data on intestinal dendritic cells come from mouse models.
Recently, a few reports have appeared on human intestinal
dendritic cells [32]. Numerous studies have demonstrated
altered DC phenotype and function in inﬂammatory bowel
disease (IBD). DCs are more activated and express increased
l ev e l so ft h em a t u ra t i o nm a rk e r sa n dT L R sa sw e lla sp r o d u c -
ing proinﬂammatory cytokines [32, 33]. Treatment of ulcer-
ative colitis patients with probiotics in combination with
corticosteroids induced a more favorable phenotype with
DC producing less inﬂammatory cytokines and lower TLR
expression [33].
PI3-Ks are activated in DCs by many stimuli, including
LPS, CpG-oligodeoxynucleotide, many of which induce IL-
12. In DCs, PI3-K inhibits p38 Map Kinase which is
essential for transcriptional activation of IL-12. Interleukin-
12 determines the balance between Th1 cellular-mediated
immunity and Th2 humoral, antibody-mediated immunity
(Figure 2(a)). Elevated IL-12 will skew towards a Th1
response [7]. Dendritic cells (DCs) are integral to the dif-
ferentiation of T-helper cells into T-helper type 1 Th1, Th2,
and Th17 subsets. Interleukin-6 (IL-6) plays an important
part in regulating these three arms of the immune response
by limiting Th1 response and promoting Th2 and Th17
responses.
Dendritic cells isolated from intestinal biopsies from
patients with inﬂammatory bowel disease have elevated
numbers of TLRs and secreted elevated cytokines. Lamina
propria DCs from inﬂamed human tissue produce higher
levels of IL-12, IL-23, and IL-10. Both shared and speciﬁc
TLR-mediated pathways exist. Shared pathways involve
MyD88, Tollip, IRAK, and TRAF6 with the other TLR ada-
ptors, TRIF, and MAL initiating more speciﬁc pathways [32].
Thus, TLRs can translate the information regarding the na-
ture of the pathogens into diﬀerential cytokine production,
thereby polarizing the immune response [6].
Increased IL-6 expression was observed in colon tissues
of DC-depleted mice, as well as a more severe colitis when
exposed to dextran sodium sulfate (DSS) compared to nor-
mal mice, demonstrating that regulation of IL-6 produc-
tion may contribute to DC-mediated control of intestinal
inﬂammation [34]. Recently, a novel PI3-K dependent path-
way to IL-6 production in CD11c DCs was reported involv-
ing cKit [35]. Dendritic cells generated from mice expressing
a catalytically inactive form of the p110δ subunit of phos-
phatidylinositol3 (PI3) kinase (p110D910A) secreted lower
amounts of IL-6 upon stimulation with cholera toxin. These
results demonstrate the importance of the c-Kit-PI3 kinase-
IL-6 signaling axis in DCs in regulating T-cell responses. In-
testinal epithelial cells in close proximity with mucosal DC
can inﬂuence localization of DC subsets thus conferring mu-
cosal DC specialization. Intestinal epithelial cells produce
thymic stromal lymphopoietin (TSLP) which inhibits IL-12
production by DCs in response to bacteria, thus promoting
Th2 responses [36].
4.1.2. Intestinal Macrophages. Resident lamina propria ma-
crophages are unique for their capacity to phagocytose and
digest microorganisms without an inﬂammatory response.
Intestinal macrophages are downregulated at both mRNA
and protein levels for multiple innate response molecules
including the receptors for LPS (CD14) [37]. Intestinal ma-
crophages are downregulated for the production of TLR-in-
duciblecytokinesincludingIL-1,IL-6,IL-8,TNFα,andIL-10
irrespective of the stimulus. This inability is associated with
the markedly reduced MyD88, Toll/TIR-domain containing
adaptor-inducing IFNβ (TRIF) adaptor protein and TRAF-
6 which results in NFκB inactivation. However, in the mu-
cosa of people with inﬂammatory bowel disease, intestinal
m a c r o p h a g e sm a ye x p r e s sh i g hl e v e l so fN F κB binding ac-
tivity, and it is thought that these cells are newly recruited
monocytes that have not been downregulated. Consistent
with the observation in DCs, the PI3-K/Akt pathway in mo-
nocytes also suppresses both Map kinases and NFκBi nr e s -
ponse to LPS resulting in decreased production of TNFα
[38].
Studies on PI3-K knockout mice support the idea that
PI3-K negatively regulates TLR activation, as signaling by
TLR2, 4, 5, and 9 is elevated in p85α deﬁcient mice and LPS-
induced IL-12 secretion is elevated in p110β deﬁcient ma-
crophages [39]. PI3-K appears to inhibit proinﬂammatory
cytokineproduction viaGSK3,aserinethreoninekinasethat
inhibits the activity of Cyclin D1, βcatenin, cjun and Myc
via phosphorylation of speciﬁc residues [40]. PI3-K acti-
vation in response to TLR stimulation leads to the inhibi-
tion of GSK3 resulting in increased IL-10 production via
CREB and its coactivator CBP binding (Figure 2(a)). GSK3
also inhibits AP-1 DNA binding which could also aﬀect
IL-10 expression. At the same time IL-12 is decreased due
to less NFκB activation because of competition for the CBP
coactivator. Phosphoinositide-dependent kinase 1 (PDK1) is
an important signaling component in the PI3-K pathway.
Primary macrophages derived from mice with conditional
knockout of PDK1 in myeloid lineages have elevated TNFα
and IL-6 mRNA and release. While immediate TLR4 sig-
naling is intact, these macrophages exhibit prolonged ubi-
quitination of TRAF-6 in response to LPS revealing a PDK-1
dependent negative feedback inhibition on NFκBa c t i v a t i o n
in macrophages [41]. Several phosphatases that regulate PI3-
K, that is, PTEN, SHP-1, and Mapk phosphatase (MKP),
have been investigated in the mechanism of the anti-inﬂam-
matory function of PI3-K in macrophages [42]. PTEN-de-
ﬁcient macrophages which have elevated PI3-K, showed re-
duced inﬂammatory cytokine, TNFα,a n dI L - 6p r o d u c t i o nJournal of Signal Transduction 7
which was accompanied by reduced MAPK activation asso-
ciated with increases in the Map kinase phosphatase, dual
speciﬁcity phosphatase 1 (DUSP1), and increases in anti-
inﬂammatory IL-10. DUSPs dephosphorylate p-Thr as well
as pSer/p-Tyr sites on Map kinases [42]. The protein tyrosine
phosphatase SHP-1 has also been shown to down regulate
TLR-induced IL-12p40 production in macrophages through
inhibition of PI3-K [43].
Other reports demonstrate a pro-inﬂammatory role for
PI3-K in monocytes viaNFκB activation, likely viathe phos-
phorylation of p65 [26]. Evidence for both pro-inﬂamma-
tory and proapoptotic signaling in response to TLRs in ma-
crophages is emerging. TLRs, via the adaptor molecule, TLR
interactingadaptorproteininducingIFN-β (TRIF)canactas
death receptors with inﬂammatory and apoptotic pathways
acting in parallel, where the ﬁnal outcome depends on the
magnitude of the responses [44].
4.2. Role of PI-3 Kinase Signaling in Intestinal T-Cells. Lam-
ina propria T (LPT) cells are poor responders towards an-
tigen-receptor triggering with very few T-cells proliferating
in response to TCR/CD3-directed stimuli [45]( Figure 2(b)).
T-cell activation via CD58/CD2 or B7/CD28 contributes to
the accumulation of T-helper cells, increased T-cell prolifer-
ation and reduced apoptosis, all characteristic of inﬂamma-
tory bowel disease. The ﬁrst in vivo evidence of the prolif-
erative hyporesponsiveness of LPT cells is an in vivo study
in rats demonstrating both antigen-receptor-dependent and
independent activation pathway downregulation [46]. Much
lower T-cell proliferation was observed after α/βTCR stimu-
lation with monoclonal antibody (mAb) compared to dual
stimulation with anti CD2 and anti-CD28 mAb, and no pro-
liferation was observed with anti-CD2 mAb alone. Hypore-
sponsiveness is restricted to the mucosa and cannot be found
in the mesenteric lymph nodes or Peyer’s patches. Work by
Kamanaka’s group explains the hypo-responsiveness of LPT
cells. They showed that α/βTCR stimulation induces Foxp3+
regulatory T-cells (Treg) with high IL-10 production. Since
these Tregs are anergic and suppressive, this likely explains
the hypo-responsiveness [21].
4.2.1. T-Cell Receptor and Costimulatory Signals. In contrast
to antigen-presenting cells, T-cells employ PI3-K to promote
inﬂammatory responses and proliferative responses such as
IL-2 and IFNγ synthesis, downstream of co-stimulatory mo-
l e c u l e ss u c ha sC D 2 8( Figure 2(b)). PI3-K and NFκBa c t i -
vation is necessary to mediate CD28-mediated proliferative
responses in CD4+ T-cells. In vitro studies using human LPT
cells have shown that LPT cells respond vigorously when
stimulated through the CD2 receptor. CD2 stimulation re-
presents an alternative mode of T-cell activation in LPT [47].
When compared to peripheral blood T-cells (PBT), LPT cells
show an increased activation of the PI3-K/AKT/GSK-3β
pathway in response to CD2 stimulation resulting in en-
hanced CD2-induced cytokine production in LPT, that is
IL-2, TNFα and IFNγ, GMCSF, and CD40L. They also
produce enhanced levels of IL-10 [48]. Although the T-cell
population in the LP is almost exclusively CD45RO+, there
were no signiﬁcant diﬀerences in CD2 activation of PI3-K
pathway in the total T-cell population of PBTs compared to
PBT CD45RO+ T-cells [49]. Thioredoxin, a thiol disulﬁde
oxidoreductase, is highly expressed in LPT and has been
shown to inactivate the lipid phosphatase PTEN, and this
may account for some of the increased CD2 responsiveness
in these cells [50]. AKT-dependent regulation of NFκBo r
nuclear retention of NFAT due to GSK3β inhibition may
contribute to the increased cytokine production in response
to CD2 stimulation in LPT. Increases in PI3-K-mediated sig-
nalinginresponsetoCD2stimulationmayalsobeassociated
withincreasesinproliferation,asarecentstudyreportedthat
the cell doubling time of LPT following CD2 stimulation is
signiﬁcantly shorter than that of PBT, and this wasassociated
with increased, Rb phosphorylation [51]. Interestingly Rb
phosphorylation is inﬂuenced negatively by inhibition of
PI3-Kinase in T lymphocytes [52].
4.2.2. TLR Signaling. An anti-inﬂammatory role for PI3-K
signaling downstream of TLRs in intestinal T-cells has been
reported. While TLR-signaling pathways in T-cells are poorly
characterized,ithasbeendemonstratedthatinCD4+T-cells,
that CpGDNA (TLR9 ligand) stimulation of PI3-K/AKT
which inhibits GSK3, attenuates excessive pro-inﬂammatory
TLR9-mediated immune responses. GSK3β promoted the
production of pro-inﬂammatory cytokines in primary mur-
ine and human intestinal T-cells while lowering secretion of
the anti-inﬂammatory IL-10 by diﬀerential regulation of
NFκBandCREBactivities[53].Themechanismislikelysim-
ilar to that described in innate immune cells (Figure 2(a)),
where in vivo blockade of GSK3β lowered NFκBa c t i v i t y
withincreasedCREBDNAbindinginintestinallymphocytes
from inﬂamed intestine. As CREB is a critical component for
IL-10 production, inhibition of its DNA binding impairs IL-
10production.Notably,theinhibitionofGSK3βdidnotalter
TLR-induced immune responses of cells from a noninﬂamed
microenvironment, while excessive pro-inﬂammatory reac-
tions of cells from inﬂamed tissue were selectively reduced
which suggests that inhibition of GSK3 could be used to
lower exaggerated inﬂammatory responses in IBD.
It has also been demonstrated that in CD4+ T-cells,
CpGDNA stimulation (TLR9 ligand) directly enhances pro-
liferation, prevents anergy and augments humoral responses
to a T-cell-dependent antigen by a MyD88 and PI3-K-de-
pendent pathway. Mutation of Y257 in the SH2-containing
TIR domain of MyD88 abrogated p85 binding, phospho-
rylation of AKT and GSK3 and IL-2 production as well as
CpG DNA driven co-stimulatory proliferative responses to
suboptimal concentrations of CD3 mAb [54]. The MyD88
death domain on the other hand was required for NFκBa c -
tivation and survival.
4.3. Role of PI3-K Signaling in Intestinal Epithelial Cells
4.3.1. IL-1R Signaling. Normal epithelial cells express only 3
out of 4 of the p110 isoforms of PI3-K (α, β and δ), and
p110δ is absent from Caco-2 cells, a widely used model
of polarized epithelium. While all the subunits appear to8 Journal of Signal Transduction
catalyze the same enzymatic reactions, there are diﬀerent
cellular responses associated with them which may be due
to diﬀerent localizations or even nonenzymatic activities.
Intestinal epithelial cells from both IBD and normal
controls have receptors for IL-1, IL-6, and GM-CSF,
but not for TNFα, although they have been detected
on adenocarcinoma cell lines. Caco-2 cells, an epithelial
adenocarcinoma cell line, have receptors for IL-6 at
both poles and for IL-1 at the basolateral surface
and to a lesser extent at the apical pole (Figure 2(c)).
T84 another intestinal adenocarcinoma cell line
has receptors for IL-6 and IL-1 only at the basolateral pole.
Functionally, IL-1 receptors enhance intestinal epithelial cell
growth and have also been shown to enhance the growth of
Caco-2 cells [55, 56]. Receptor density is greater on surface
versus crypt epithelial cells [55].
Although IL-1α is constitutively expressed by epithelial
cells, the expression of the pro-form of IL-1β is induced by
NFκB and later processed to the active form. Interleukin-1β
and the type 1 IL-1R have been implicated in protection and
control against several enteric pathogens including Staphylo-
coccus aureus, Salmonella enteric, and Shigella ﬂexneri as well
as chemical-induced colitis [57–59]. IL-1R signaling protects
mice from the attaching and eﬀacing pathogen Citrobacter
rodentium. Upon infection, mice lacking the type 1 IL-1R
demonstrate increased mortality and severe colitis. It is
thought that the protective eﬀects against this pathogen
might be mediated by the constitutive IL-1α via a MyD88-
dependent pathway. IL-1R−/− mice fail to produce IL-6
and IFNγ [60]. It is not known if the protective eﬀects of
IL-1 are mediated by PI3-K. However, inhibition of PI3-K
resulted in increased chloride secretion and barrier dysfunc-
tion suggesting that agonists that induce PI3-K may protect
epithelial cells from immune-mediated apoptosis as well as
function to limit chloride secretory diarrhea [61].
Intestinal epithelial cells are capable of inducing an acute
phase response similar to hepatoma cells [62]. Intestinal
epithelial cells produce IL-6 in response to IL-1. IL-6 leads to
increased protective acute phase responses following tissue
damage or infection [63]. In the Caco-2 cell line a PI3-
kinase-dependent role for IL-1 induction of IL-6 gene tran-
scription was reported [22]. This involved a PI3-K/AKT-de-
pendent pathway upstream of the transcription factor ac-
tivator protein 1 (AP-1) (Figure 2(c)). This pathway involved
a kinase in the IKK complex, IKKα, which is phosphorylated
by AKT on Thr23 upstream of AP-1. This is likely indepen-
dent of the canonical AP-1 pathway via JNK activation and
suggests that there is an alternative AP-1 activation pathway
in intestinal epithelial cells (unpublished data). It is likely
that this IL-1-induced pathway-mediating IL-6 transcription
could also mediate the protective eﬀects of IL-1 and that
NFκB may be involved in mediating more acute increases in
IL-6 in immune cell types.
4.3.2. TLR Signaling. Most intestinal epithelial cells are
potently responsive to ﬂagellin the speciﬁc ligand for TLR5
and hypo-responsive to TLR4 (LPS receptor). TLR4 deﬁ-
ciency makes the mouse susceptible to Dextran sulfate-in-
duced colitis and feeding LPS to normal mice provides
protection against DSS-induced colitis. This suggests that
TLR4activationbyLPSmayprovidebeneﬁcialeﬀectssuchas
promoting epithelial cell proliferation and enhanced wound
healing at the intestinal epithelium [64]. Despite the hypo-
responsiveness of TLR4 in various intestinal epithelial cells,
uncontrolled TLR4 activation is associated with necrotizing
enterocolitis. Preterm infants show a higher expression of
TLR4 in the intestine than normal infants rendering preterm
infants highly susceptible to inﬂammation due to TLR4
activation by enteric microbes [65].
TLR4signalinghasbeenshowntoexacerbateCitrobacter.
rodentium infection. Both bacterial LPS and infection with
C. rodentium inactivate Foxo3α in intestinal epithelia in vivo
and in vitro [66, 67]. Foxo3 belongs to the family of tumor
suppressor family of Forkhead transcription factors. It is
located in the nucleus and regulates genes involved in cell
cycle, apoptosis, and metabolism. Phosphorylation of Foxo
is mediated by PI3-K as well as by IKK. Translocation to the
cytoplasm by 14-3-3-mediated nuclear export, together with
proteasomal degradation, mediates its inactivation [68, 69].
LPS and TNFα-mediated Foxo inactivation in HT-29 cells
was controlled by the PI3-K pathway. Blocking PI3-K leads
to attenuation of LPS and TNFα-induced IL-8 secretion in
HT-29cellsandLPSinducedIL-8is increasedinHT-29 cells,
anintestinalepithelialadenocarcinomacelllinewithsilenced
Foxo3α [66, 67]. IL-8 is a pro-inﬂammatory chemokine that
is a chemo-attractant for neutrophils and lymphocytes. LPS
was associated with down regulating the NFκB inhibitor,
IkBα, and in the case of TNFα, IKK was also involved in
the pathway. It was also shown that Foxo3 localization in the
cytosol and Foxo deﬁciency lead to severe intestinal inﬂam-
mation in vivo in a Foxo3-deﬁcient mouse. Foxo3-deﬁcient
mice develop more severe inﬂammatory responses to DSS
compared to wild type mice [66].
TLR5 activation is also associated with IBD [70]. It has
been suggested that activation of diﬀerent isoforms of PI3-K
may explain the diﬀerential outcomes on TLR5 activation in
epithelial cells.
TLR5 is localized on the basolateral side of epithelial mu-
cosa,andresponsivenessisthereforeincreasedwithimpaired
barrier function as in IBD. Inhibition of PI3-K with wort-
mannin or LY204002 increased both IL-6 and IL-8 produc-
tion in response to ﬂagellin in T84 cells [71]. Systemic cyto-
kine release in response to intraperitoneal injections of ﬂa-
gellin in p85−/− mice was signiﬁcantly higher compared to
heterozygous littermates. Another study in T84 cells demon-
strated a PI3-K dependent anti inﬂammatory pathway acti-
vated by Salmonella [72]. In this study, inhibition of PI3-K
in T84 cells resulted in increased IL-8 production. Contrary
tothese2studies,apaperbySangetal.,(2006)demonstrated
that inhibition of PI3-K using dominant negative p85,
Akt or LY294002 reduced IL-8 production in response to
ﬂagellin indicating that PI3-K augments ﬂagellin-mediated
inﬂammatory responses in intestinal epithelial cells [73].
Zeng et al. 2006 showed that ﬂagellin induces a pro-inﬂam-
matory cascade, and in the absence of NFκB or PI3-K/Akt
signaling, apoptosis is initiated in parallel [74].Journal of Signal Transduction 9
5. EffectofPI3-KInhibitioninMouseModelsof
InﬂammatoryBowelDisease
5.1. Eﬀect of PI3-Kγ Inhibition in Dextran Sulphate Sodium
(DSS) and 2,4,6-Trinitrobenzenesulphonic Acid (TNBS)
Mouse Models of Intestinal Inﬂammation. The role of PI3-K
in mouse models of IBD is beginning to emerge. Using spec-
iﬁc pharmacological inhibitors of PI3-Kγ, attenuation of
DSS-induced colitis was demonstrated [75]. The inhibitor,
AS605240, was administered starting on the same day as
DSS administration in the acute colitis model and on day
11 after DSS administration in the chronic colitis model
(Figure 1(b)). AS605240 had protective and therapeutic
eﬀects in both acute and chronic DSS colitis in vivo
and signiﬁcantly decreased the clinical and histopatholog-
ical symptoms of DSS-fed mice and increased survival
in the acute model. This was accompanied by decreases
in phosphorylated Akt in immunological cells in both
inﬂamed colon and spleen of DSS-fed mice and decreases
in macrophage together with neutrophil and CD4+ T-cell
inﬁltration. Additionally, levels of the pro-inﬂammatory IL-
1β,T N F α and IFNγ in the colon was decreased by AS605240
with accompanying restored levels of the anti-inﬂammatory
cytokine IL-4.
Another study of the eﬀects of PI3-Kγ on acute DSS
colitis was done using PI3-Kγ mutant mice harboring a kin-
ase dead form of this PI3-K isoform [76]. Both clinical and
histopathological parameters showed that severity of colitis
was signiﬁcantly reduced in PI3-Kγ-kinase inactive mice
compared to controls. This was accompanied by signiﬁcantly
more pro-inﬂammatory Th1 cytokines such as IL-12, TNFα,
and IFNγ and more IL-10, suggesting a role for PI3-Kγ in
thenegativeregulationofthesecytokines.Increasednumbers
of resident macrophages and T-cells in the colonic lamina
propria in the unstressed condition were also observed,
suggesting that PI3-Kγ may not only play a role in leukocyte
recruitment in response to injury and inﬂammation but also
regulate emigration of leukocytes from the lamina propria
under physiological conditions. The failure to recruit new
leukocytes to the mucosa upon DSS treatment of the mice
suggests that PI3-Kγ functions in lamina propria leukocyte
traﬃcking.
Another study using PI3-Kγ knockout mice in which the
isoform is absent, were treated with DSS [77]. This is an
important diﬀerence as PI3Kγ also has a kinase-independent
role as a scaﬀold protein. Similar to the results above, abs-
ence of a functional PI3-Kγ protects mice from DSS-induced
colitis and the knock out mice fail to recruit T-cells and
macrophages to the colon after DSS treatment. One of the
major diﬀerences with the previous study is that they ob-
served a decrease in TNFα production in the PI3-Kγ knock-
out mice upon treatment with DSS. Because a mouse bear-
ing a point mutation in the kinase domain, making the
PI3Kγ kinase dead was used, this might resemble the eﬀects
similar to small-molecule inhibition. Thus, absence of kinase
activity in the PI3-Kγ kinase inactive mouse might be re-
sponsible for the observed increases in TNFα.T h i ss t u d y
demonstrated that PI3-Kγ deﬁcient mice, in addition to
having less colonic inﬂammation also had a lower incidence
of colitis-associated tumors. These studies all compliment a
priorstudyshowingthatintravenousadministrationofsmall
interfering RNAs against p85α attenuates inﬂammation in a
DSS mouse model of colitis [78]. The fact that increases in
AKT phosphorylation are observed in intestinal mucosa of
patients with ulcerative colitis suggests that inhibition of this
pathwaymay prove eﬃcaciousin thetreatmentof thedisease
in humans [79].
More recently, it has been reported that the PI3-Kγ in-
hibitor, AS605240, ameliorates TNBS induced colitis in
mice by aﬀecting the functional activity of Treg cells,
CD4+CD25+FoxP3+ cells [80] .T h eT N B Sm od e lo fI B Dh a s
an elevated Th1 response with macrophages producing large
amounts of IL-12, IFNγ,a n dI L - 1a n di sam o d e lm o r ef o r
Crohn’s disease. Oral administration of the drug reduced
colonic expression of IL-1β, the chemokine, CXCL-1/KC,
macrophage inﬂammatory protein, MIP-2, and TNFα in
an NFκB-dependent manner. Phosphorylation of the p65
subunit of NFκB signiﬁcantly decreased in colon tissue. In-
creases in CD25 FoxP3 and IL-10 expression were observed
in isolated lamina propria of AS605240-treated mice
which coincided with increased percentages of Treg
CD4+CD25+FoxP3+ cells. Thus, these results suggest that
AS605240 has multiple inﬂammatory targets via NFκB in-
hibition, while increasing the numbers of anti-inﬂammatory
Treg cells.
Another PI3-K inhibitor PIK-75 which inhibits both the
α and γ isoforms has also been shown to attenuate DSS-
induced colitis by suppressing the production of pro-inﬂam-
matory mediators in an NFκB-dependent manner as well as
reducing the inﬂammatory cellular inﬁltrate into the colonic
interstitium [78]. Given the fact that PIK-75 is known to
exhibit anticancer activity, this study reinforces the cross-
therapeutic functionality of potential drugs. PIK-75 potently
inhibits in vitro LPS-induced production of TNFα and IL-6
from freshly isolated human monocytes with corresponding
inhibition of NFκB. Interestingly however, PIK-75 under
in vitro conditions markedly inhibited the production of
IL-10 from human PBMCs stimulated with a combination
of anti-CD3 and anti-CD28 MAbs. RT-PCR analysis also
demonstrated that PIK-75 reduced IL-10 mRNA in the colon
of DSS-treated mice.
6. PI3-Kinase Inhibitionin
Inﬂammation-InducedColorectal Cancer
ThePI-3Kpathwayhasbeenshowntoplayanimportantrole
intheregulationofintestinalepithelialproliferation,survival
and wound healing. It will therefore be important to address
the role of each isoform in both normal cellular homeostasis
and in disease before using isoform speciﬁc inhibitors
clinically [81]. Each isoform is capable of regulating multiple
cellular functions but with signiﬁcant redundancy which
may also limit the clinical use of isoform speciﬁc inhibitors.
Class 1A and class 3 PI3-kinases are strongly expressed in
colonic epithelial carcinoma cell lines, and there is increased
PI3-kinase activity in colorectal carcinoma specimens. Both
p110α and p110β play important roles in human colon10 Journal of Signal Transduction
cancer growth: p110β has a speciﬁc role in de novo DNA
synthesis, and p110α determines cell survival [82]. The
transforming functions of PI3-Kγ in colon carcinoma are
linked to disruption of intercellular adhesion and myeloid
cell invasion [83].
There are potentially multiple mechanisms for PI-3 kin-
ase constitutive activation in colon cancer, for example, di-
rect PI-3-K activation through PIK3CA mutation, PTEN
loss, activation of AKT itself through activating mutations
in its PH domain, receptor tyrosine kinases such as ERBB3
activation as well as KRAS (which is mutated in up to 45%
of colorectal cancers) and which is upstream of both the
PI-3 kinase and Map kinase pathways [84]. Some colorectal
tumors are mutated in more than one of these pathways.
Therefore, the success of PI3-K inhibitors alone will depend
on the type of mutation manifested in the patient. It is likely
that a more targeted and personalized medicine approach
will be required for success, with speciﬁc PI3-K inhibition
used in conjunction with conventional cytotoxic therapies. A
positive predictor of response may be detection of activating
mutations in the PI-3-K gene itself, while KRAS mutations
would likely be a negative predictor of response. It has
recently been shown that receptor tyrosine kinases have con-
trol of PI-3K signaling in human KRAS mutant colorectal
cancers and PI3-K may be involved in maintenance of the
tumorphenotypeaftertransformation.Infactonlyabout7%
of patients in a recent study were reported to have a PIK3CA
mutation without a KRAS mutation. The percent of patients
that might beneﬁt from PI3-kinase inhibitors may increase
whenmoreisknownaboutPTENregulationinthesecancers
[85, 86].
Concern fromtheinitial ﬁrstgenerationPI3-K inhibitors
was that the second generation inhibitors might be toxic
in humans was unwarranted. Third generation inhibitors in
preclinical models are showing promise as anti-cancer ther-
apeutics. The importance of PI3-K downstream of insulin
signaling was a further concern; however, in early clinical
evaluation of the inhibitors the only eﬀect has been a rise
in insulin. Several inhibitors of PI3-K pathway are currently
in clinical development for colorectal cancer and have been
shown to potentiate the eﬀects of cytotoxic therapy. This
is likely because PI3-K pathway mediates tumor survival
following cytotoxic therapy. Perifosine, in phase 11 clinical
trials, is an inhibitor of AKT and has shown some promise in
combination with other inhibitors. MK-2206, also an AKT
inhibitor, has recently completed phase 1 study. The reader is
referred to a recent paper of these and other PI3-K pathway
inhibitors currently being tested in colorectal cancer [85].
7. Conclusions andFutureStudies
The intestinal mucosa has adapted an immune system to
respond appropriately to commensal and pathogenic bacte-
ria to maintain immune homeostasis. The PI3-kinase sig-
naling pathway downstream of TLRs, TCR, and co-stim-
ulatory receptors is an important mediator of this immune
homeostasis. Dysregulation of this pathway in innate and
adaptive immune cells and in the intestinal epithelium
can lead to inﬂammatory disorders including inﬂammatory
bowel disease and its associated cancers. Great strides have
been made in the development of isoform speciﬁc PI3-K
inhibitors and have lead to the identiﬁcation of PI3-Kγ as an
important isoform in intestinal inﬂammation; it will be nec-
essary to test the eﬃcacy of these inhibitors in terms of their
future therapeutic use in humans.
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